Oxford Cannabinoid Technologies Holdings, one of the UK’s few remaining pharmaceutical cannabis companies, appears to have entered administration.
Earlier this week, Jazz dismissed a patent claim against Apotex, Canada’s largest generic drug producer, as it reached a settlement with the company, the details of which were undisclosed.
Oxford Cannabinoid Technologies (“OCT” or “the Company”) is pleased to announce the successful completion of ‘proof of concept’ of its
Chill Brands [stock_market_widget type=”chart” template=”line” assets=”CHLL.L” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] The CBD and
Last week, UK biotechnology firm Oxford Cannabinoid Technologies (OCT), one of the first cannabis companies in history to list on
Synbiotic [stock_market_widget type=”chart” template=”line” assets=”SBX.DE” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] German cannabis group SynBiotic
MGC Pharmaceuticals / Argent BioPharma [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”MXC.L” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] MGC Pharmaceuticals
This week, British pharmaceutical cannabis firm Oxford Cannabinoid Technologies (OCT) announced that the ‘final dose’ in its crucial Phase I
Akanda Akanda unveiled its unaudited financial figures for the six months to the end of June 2022, two weeks after
Oxford Cannabinoid Technologies Oxford Cannabinoid Technologies (OCT) has seen its share price jump by more than 20% this week after
AFTER a month of relatively positive upwards trajectory for many European cannabis stocks, this week has seen a return to
OXFORD Cannabinoid Technologies Holdings plc (LSE: OCTP, OTCQB: OCTHF), the pharmaceutical company developing prescription cannabinoid medicines targeting the US$ multi-billion
GAVIN Sathianathan, a founder member of Oxford Cannabinoid Technologies (OCT), published a bombshell letter to fellow investors last week laying
AS European Cannabis stocks continue their battle against external market forces, it has been internal battles which made the headlines
OXFORD Cannabinoid Technologies Holdings plc (LSE: OCTP, OTCQB: OCTHF), the pharmaceutical company developing prescription cannabinoid medicines targeting the US$ multi-billion
On the 1-year anniversary of the first cannabis company to list on the London Stock Exchange, we examine the reaction to a number of significant announcements from some of the UK’s biggest cannabis players, making for an eventful week in the markets.
Richard Guy Hathaway has been appointed to the Board as a Non-Executive Director, as a representative of Imperial Brands Ventures Limited (“Imperial”), with effect from 1 February 2022.
OCT believes Stemtech’s technology provides an in vitro translational model that will better predict results in humans.
We won’t spam you
